---
title: Repotrectinib in <em>ROS1</em> Fusion-Positive Non-Small-Cell Lung Cancer
date: '2024-01-10'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38197815/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240110170457&v=2.18.0
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: Repotrectinib had durable clinical activity in patients
  with ROS1 fusion-positive NSCLC, regardless of whether they had previously received
  a ROS1 TKI. Adverse events were mainly of low grade and compatible with long-term
  administration. (Funded by Turning Point Therapeutics, a wholly owned subsidiary
  of Bristol Myers Squibb; TRIDENT-1 ClinicalTrials.gov number, ...'
disable_comments: true
---
CONCLUSIONS: Repotrectinib had durable clinical activity in patients with ROS1 fusion-positive NSCLC, regardless of whether they had previously received a ROS1 TKI. Adverse events were mainly of low grade and compatible with long-term administration. (Funded by Turning Point Therapeutics, a wholly owned subsidiary of Bristol Myers Squibb; TRIDENT-1 ClinicalTrials.gov number, ...